Raynaud's phenomenon and vitamin D

Rheumatology International

Volumn 33, Issue 3, 2013, Pages 751-755

  Hélou, Josiane ^a   Moutran, Roy ^a   Maatouk, Ismael ^a   Haddad, Fady ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

Cold; Ergocalciferol; Phenomenon; Raynaud; Vitamin D

Indexed keywords

ERGOCALCIFEROL; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADULT; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RAYNAUD DISEASE; VITAMIN D;

EID: 84879692777     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2445-x     Document Type: Article

References (28)

1. Baumhäkel M, Böhm M (2010) Recent achievements in the management of Raynaud's phenomenon. Vasc Health Risk Manag 15(6):207-214
2. Herrick AL (2005) Pathogenesis of Raynaud's phenomenon. Rheumatology 44:587-596
3. Dhesi KJ, Moniz C, Close JC, Jackson SH, Allain TJ (2002) A rationale for vitamin D prescribing in a falls clinic population. Age Ageing 31:267-271
4. Gannagé-Yared MH, Maalouf G, Khalife S et al (2009) Prevalence and predictors of vitamin D inadequacy amongst Lebanese osteoporotic women. Br J Nutr 101(4):487-491
5. Raynaud M (1888) Local asphyxia and symmetrical gangrene of extremities 1862. New researches on the nature and treatment of local asphyxia of the extremities 1874 (trans: Barlow). New Sydenham Society
6. Lewis T (1929) Experiments relating to the peripheral mechanisms involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart 15:7-101
7. Silman A, Holligan S, Brennan P, Maddison P (1990) Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ 301:590-592
8. Wigley FM (1993) Raynaud's phenomenon. Curr Opin Rheumatol 5:773-784
9. Wigley FM (2002) Clinical practice. Raynaud's Phenomenon. N Engl J Med 26;347(13):1001-1008
10. LeRoy EC, Medsger TA Jr (1992) Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 10:485-488
11. Kaheleh B, Matucci-Cerinic M (1995) Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 38:1-4
12. Rajagopalan S, Pfenninger D, Kehrer C et al (2003) Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum 48(7):1992-2000
13. Bakst R, Merola JF, Franks AG Jr, Sanchez M (2008) Raynaud's phenomenon: pathogenesis and management. J Am Acad Dermatol 59(4):633-653
14. Kawaguchi Y, Takagi K, Hara M et al (2004) Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 50(1):216-226
15. Pilz S, Tomaschitz A (2010) Role of vitamin D in arterial hypertension. Expert Rev Cardiovasc Ther 8(11):1599-1608
16. Harris RA, Pedersen-White J, Guo DH, Stallmann-Jorgensen IS, Keeton D, Huang Y, Shah Y, Zhu H, Dong Y (2011) Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. Am J Hypertens 24(5):557-562. (Epub 2011 Feb 10)
17. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1,25- Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238
18. Martinesi M, Bruni S, Stio M, Treves C (2006) 1,25-Dihydroxyvitamin D3 inhibits tumor necrosis factor-alpha-induced adhesion molecule expression in endothelial cells. Cell Biol Int 30:365-375
19. Helming L, Bose J, Ehrchen J et al (2005) 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 106:4351-4358
20. Yu S, Bruce D, Froicu M, Weaver V, Cantorna MT (2008) Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci USA 105:20834-20839
21. Pittas AG, Lau J, Hu FB, Dawson-Hughes B (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92:2017-2029
22. Janini SD, Scott DG, Coppock JS, Bacon PA, Kendall MJ (1988) Enalapril in Raynaud's phenomenon. J Clin Pharm Ther 13:145-150
23. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E et al (1999) Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a 15-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646-2655
24. Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI et al (2001) Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 40:1038-1043
25. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985-3993
26. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Int Med 120:199-206
27. Kumana CR, Cheung GT, Lau CS (2004) Sever digital ischemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 63:1522-1524
28. Hulshof MM, Bavinck JN, Bergman W, Masclee AAM, Heickendorff L, Breedveld FC, Dijkmans BA (2000) Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 43:1017-1023